Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 4/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608281 | 0.89 | NR1H2 (0.36) | CHRNB2CHRNA4HSP90AA1HSP90AB1GPR119 | |
| SCHEMBL609142 | 0.87 | ATXN2 (0.33) | HSP90AA1HSP90AB1HDAC8MEN1KMT2A | |
| SCHEMBL10145590 | 0.80 | CHRNA3 (0.37) | CHRNB2CHRNA4GPR119 | |
| SCHEMBL609058 | 0.76 | NR1H2 (0.34) | HSP90AA1HSP90AB1HDAC8MEN1KMT2A | |
| SCHEMBL30149908 | 0.76 | IL1B (0.39) | GPR119 | |
| SCHEMBL7859303 | 0.70 | ALDH1A1 (0.38) | GPR119HDAC8MEN1KMT2ASRC | |
| SCHEMBL20241498 | 0.69 | EPHA2 (0.50) | — | |
| SCHEMBL23377691 | 0.69 | PIK3CD (0.43) | HSP90AA1HSP90AB1GPR119MEN1KMT2A | |
| SCHEMBL7409578 | 0.68 | CHRNA3 (0.45) | CHRNB2CHRNA4GPR119 | |
| SCHEMBL7409573 | 0.68 | CHRNA3 (0.45) | CHRNB2CHRNA4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040991-A1 | 3-AZABICYCLO [4.1.0] HEPTANES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | CHRNB2 120/4885CHRNA4 69/4885HSP90AA1 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.